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= A bs t ra c t =The prevalence of oncogenic human papillomavirus (HPV) type 16 
and 18 was investigated by polymerase chain reaction (PCR) method in cervical 
scrapes omitting prior DNA extraction. Samples were obtained from 70 
gynecologic inpatients with normal cervix and 160 women with cervical 
neoplastic lesion ( N = 50 in cervical intraepithelial neoplasia (CIN) I, N = 50 in 
CIN 11, N = 30 in CIN 111, N = 30 in invasive cervical cancer). Eight members were 
excluded from the data due to  failure of pglobin amplification during the PCR 
procedure. The HPV 16 prevalence rate was 19.1 % (13/68) in the normal 
group, 38.8 % (19/49) in CIN I, 57.1 % (28/49) in CIN 11, 75.9 % (22/29) in CIN 
111, 88.9% (24/27) in invasive cancer. For HPV type 18, DNA positivity was 4.4 % 
(3/68), 8.2 % (4/49), 12.2 % (6/49), 13.8 % (4/29), 18.5 % (5/27), 
respectively. In the whole series a consistent correlation was found between HPV 
positivity and severity of cervical lesion. HPV 16 was the more prevalent type and 
about five times more common than HPV 18. These results suggest that HPV 16 
and 18 may be strongly associated with carcinogenesis of cervical cancer. The 
high risk HPV typing by direct PCR from cervical scrapes can be used as a useful 
marker for the presence of neoplastic cells and also served as  a simple tool in 
identifying women who are at  risk of developing dysplasia and cervical cancer. 
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Papanicolaou's (PAP) cytologic screening has 
INTRODUCTION been used to detect cervical cancer and its 
precursor lesions and has contributed much in 
Cancer of the uterine cervix is the most the early diagnosis or cervical neoplastic lesion 
common gynecologic malignancy in Korea. (Miller 1986). But the difficulty of predicting 
which cervical lesion will show progression or 
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additional prognostic markers. Over recent years 
much interest has focusecj on human 
papillomavirus (HPV) as a possible etiologic 
factor of cervical cancer (Munoz et al. 1988; Van 
den Brule et a/. 1989,1990a,1990b; Zur Hausen 
et al. 1989a, 1989b). Until now over 60 different 
HPV types are identified by molecular biologic 
techniques. Among these, HPV type 6 and 11 
are mainly detected in benign lesions such as 
condyloma accuminatum and therefore, they are 
called the benign low risk types (Gissmann et a/. 
1983; Schneider et a/. 1987).0n the other hand 
HPV type 16, 18, 31, 33, 35 have been classified 
as high risk types because they have been 
much more frequently detected in either CIN or 
cervical cancer than in normal cervical 
epithelium (Buckley et a/. 1981; Maureen et a/. 
1992; Munoz et a/. 1988; Peter et a/. 1989; Young 
et a/. 1989). In vitro studies have also shown that 
transfection of DNA from HPV 16, 18, 31 and 33( 
but not HPV 6b and 11) induced immortalization 
and aneuploidy in normal human genital 
keratinocyte (Barnes et a/. 1990; Schlegel et a/. 
1988). This suggests that high risk types are 
strongly associated with the carcinogenesis of 
cervical cancer. Among the above high risk HPV 
types, type 16 and 18 have been found at a 
higher prevalence and HPV type 18 is suspected 
to be associated with more aggressive and 
rapidly progressive cancer (De Villiers et a/ . ,  
1987; Lorincz et a/ .  1987; Mark et a/. 1991; 
Walker et a/. 1989; Xiao et a/. 1988).Polymerase 
chain reaction (PCR) can be used for the 
detection of HPV in crude cervical scrapes and 
therefore applied to the mass screening of HPV 
in a rapid, sensitive and reliable manner. But still 
great variations are present in the HPV 
prevalence rates among studies probably due to 
geographical difference, methods applied, 
sample contamination, HPV subtypes included 
and so on. To define the level of association of 
specific HPV types with cervical neoplasia in 
Korean women, we studied the prevalence rate 
of HPV type 16 and type 18 by PCR in the crude 
cervical scrapes from normal cervix, CIN and 
invasive cancer. 
MATERIALS AND METHODS 
Study group and sample preparation 
Cervical scrapes were obtained from 230 
patients who were admitted to the Gynecologic 
department, Seoul National University Hospital. 
Normal control cervical samples were taken from 
70 gynecologic in-patients who planned to 
undergo hysterectomy because of non-cervical 
gynecologic disease, colpos-topically normal 
cervices and no history of abnormal cervical 
cytology. Hysterectomy specimens were 
pathologically reconfirmed to have no neoplastic 
lesion in the cervix. Pathologic samples were 
obtained from 130 patients with CIN ( N = 50 for 
CIN I, N = 50for CIN 1 1 ,  N = 30for CIN Ill ) and  
30 patients with invasive cancer. 8 patients were 
excluded due to poor amplification of eglobin 
during the PCR procedure. Cervical cells were 
collected from the transformation zone and / or 
endocervical canal with a cytobrush and were 
suspended in 1 ml cold phosphate buffered 
saline (PBS). Tubes with exfoliative cervical cells 
were refrigerated at -20" C if necessary. 
The suspension was centrifuged at 4" C for 5 
minutes at 6,000 rpm and the pellet was 
resuspended in 10 pl of 0.1 N NaOH-2 M NaCl 
solution and vortexed. After boiling at 95" C for 2 
minutes, 90p1 TE buffer solution (10 mM tris 
hydrochloride - 1 mM EDTA) was added and the 
samples were stored at 4 " C. 
In each assay negative(Neuroblastoma 
tissue DNA) and positive controls (CaSki and 
HeLa cell DNA for HPV 16 and 18, respectively) 
were included. Cells were digested at 37" C for 2 
hours with 100 pg/ml proteinase K in lOmM Tris- 
HCI, 1 mM EDTA, 1 % Sodium dodexyl sulfate 
(SDS). Thereafter DNA was separated by three 
extractions with phenol and chlorform/isoamyl 
alcohol (24: l  vol/vol). 50mg/ml RNAse A was 
added to remove RNA. DNA concentration was 
determined using a spectrophotometer (0.D.260 
I 0.D.280 = 1.8 ). 
The genomic region chosen for HPV type 16 
and type 18 was within the E6 open reading 
frame (ORF) whose DNA remains after viral 
integration into host genomic DNA. The 
suitability of the DNA for amplification in each 
cervical specimen was confirmed by successful 
amplification of P-globin by using P-globin 
specific primer (supplied from Clontech Co.) as 
an internal reaction control. HPV 16 and 18 type- 
specific primer sequences (by Young) are 
shown in Table 1. The size of amplified products 
was 120 base pair (bp) for HPV 16, 100 bp for 
HPV type 18 and 260 b p  for P-globin, 
respectively. 
HPV DNA amplification by PCR 
Amplification of HPV DNA was carried out in 
100 p1 of reaction mixture containing 10 p1 of 
sample (1.0 pI of DNA in CaSki, HeLa and 
neuroblastoma cells ), 25 mM KCI, 20 mM Tris- 
HCl ( pH 8.3 ), 1.5 mM MgC12, 0.05 O/O Tween 20, 
100 p1 of each dNTP (dATP, dGDP, dCTP and 
dTTP) (Perkin Elmer Cetus),  0.25 p M  of 
upstream primer, 0.25 pM of down stream 
primer, 0.15 pM of P-globin primer, 0.01 % 
gelatin, and 2.5 unit of the thermostable Taq 
DNA polymerase. The sample was overlaid with 
mineral oil (100 pl) to prevent evaporation and 
subjected to 35 cycles of amplification by 
programmed heat block (Hybaid thermal 
reactor: Hybaid Ltd., U.K.). Each cycle involved 
heating to 95" C for 1 minute (Primer annealing), 
and heating to 72°C for 2 minutes (Chain 
extension). 10 pl of each PCR mixture was mixed 
with loading dye and loaded onto an 8 % 
polyacrylamide gel and electrophoresis was 
carried out for 50 minutes at 100 volts. The gel 
was then stained in 1 pglml ethidium bromide 
solution for 30 minutes and visually inspected 
under ultraviolet light and photographed by 
black and white polaroid ( ASA 3,000 ). 
Statistical analysis 
Association between the severity of the 
lesion and the HPV DNA positive rate was 
analyzed by score test for trend. A p-value below 
0.05 (P < 0.05) was considered to indicate a 
significant difference. 
RESULTS 
8 out of 230 cases (2 cases in the normal 
group, 3 cases in the CIN group,3 cases in the 
invasive cancer group) were excluded because 
P-globin was not amplified during PCR. There 
was amplification of CaSki cell DNA (Positive 
control of HPV 16 DNA) and HeLa cell DNA 
(Positive control of HPV 18 DNA) by PCR but no 
amplification in neuroblastoma cell ( Negative 
controls ) (Fig. 1). HPV type 16 DNA yielded a 
band in 120 bp and HPV type 18 DNA in 100 bp, 
and the bands are seen in Fig. 2. The 
Table 1 .  Sequences of oligonucleotide primers used in PCR procedure 
HPV type Sequence(5'-3') Genomic location 
Size of amplified 
Products (bp) 
- .- 
Type specific primers# 
HPV 16 A : TCAAAAGCCACTGTGTCCTG 421 - 440 120 
B : CGTGTTCTTGATGATCTGCA 521 - 540 
HPV 18 A : ACCTTAATGAAAAACGACGA 463 - 482 100 
B : CGTCGTTGGAGTCGTTCCTG 543 - 562 
PGlobin primert 
HPV 18 A : GAAGAGCCAAGGACAGGTAC 
6 : CAACTTCATCCACGTTCACC 
# Data from Young et a1.(1989) 
t Data from Resnick etal. (1990) 
A : Upstream Primer, 6: Downstream Pr~mer 
DISCUSSION 
Fig. 1 .  Polyacrylamide gel electrophoresis of control 
samples amplified by polymerase chain reaction 
(PCR). Lane M: Size marker. Lane C: CaSki cell 
DNA (Positive control for HPV 16). Lane H. HeLa 
cell DNA (Positive control for HPV 18). Lane C + 
H: Mixture of CaSki and HeLa cell DNA. Lane N: 
Neuroblastoma (Negative control). 
Fig.  2. Polyacrylamlde gel electrophoresis of the 
samples from cervix cancer patients amplified by 
polymerase chain react ion. Lane 1-9.  DNA 
samples from cervix cancer patients. Lane M:  
size marker. 
prevalence rate of HPV type 16 and HPV 18 
DNA is in table 2. HPV 16 DNA prevalence rate 
was 19.1 % (13168) in normal cervices, 38.8 O/O 
(19149) in CIN 1 ,  57.1 % (28149) in CIN 1 1 ,  75.9 % 
(22/29) in CIN 1 1 1 ,  88.9 % (24127) in invasive 
cancer. HPV 18 positive rate was 4.4 % (3168) in 
normal cervices, 8.2 % (4149) in CIN 1 ,  12.2 "io 
(6149) in CIN 1 1 ,  13.8 % (4129) in CIN Ill and 18.5 
% (5127) in cervical  cancer.  A consistent 
correlation was found between the severity of the 
cervical lesions and the positive rate of the HPV 
16 or HPV 18 DNA ( ~ 2  = 52.7, P < 0.05 for HPV 
16. x2 = 5.4, P < 0.05 for HPV 18). In the whole 
series HPV 16 was almost five times more 
common than HPV 18. 
Human papillomaviruses (HPV) have been 
implicated in the development of malignant 
lesions of the female genital tract. Over 60 
different types of HPV types were identified and 
among these, HPV type 16 and 18 were most 
frequently detected in dysplastic and mal~gnant 
lesions of the cervix (De Villiers et a/. 1987; Mark 
ef a/.  1991 ; Pater et a/. 1986; Xiao et a/. 1988). It is 
thought that oncogenic HPV DNA integration into 
human genome is often accompanied by  
deletion of parts of the viral genome. For 
instance, the integration of HPV 16 is often 
accompanied by a partial deletion of the El-E2 
open reading frame(0RF). It is speculated that 
the E2 proteln has a regulatory function for E6 
and E7 gene expression and the deletion of this 
gene gives rise to consistent E6 - E7 gene 
transcription with maintenance of oncogenic 
phenotype (Howley 1988).  The E6 and E7 
proteins were found to bind to the p53 and the 
ret inoblastoma gene products which are 
regarded as tumor suppressor genes. Along with 
this, some cofactors are suspected to play a role 
in malignant transformation because only a few 
HPV positive women progress to neoplastic 
lesion (De Villiers et al. 1992). 
At present the only reliable way to detect 
and type HPV is nucleic acid detection method, 
and there are numerous methods of detecting 
HPV DNAs such as Southern blot hybridization, 
dot spot method, filter in situ hybridization 
(FISH), DNAIRNA in situ hybridization and 
polymerase chain reaction. The Southern blot 
method is considered sensitive (detect a level up 
to 1 pg  HPV DNA) and specific but laborious 
and requires a large amount of DNA (10 pg) .  
Moreover there have been questions about the 
reproducibility and specificity in HPV typing by 
this method.  Dot spot technique requires 
relatively small quantities of DNA (0.3 -1 pg) and 
can detect a level as low as 0.5 - 1 pg  HPV 
DNA. But this procedure can only be performed 
Table 2. HPV 16 and HPV 18 positive rate by cervical histology 
Total Cases Positive rate 
entries included HPV 16 HPV 18 HPV 16 or 18 
Normal 70 68 13 (19.1%) 3 (4.4%) 15 (22.1 %) 
CIN I 50 49 19 (38.8%) 4 (8.2%) 22 (44.9%) 
CIN II  50 49 28 (57.1 %) 6 (12.2%) 31 (63.3%) 
CIN Ill 30 29 22 (75.9%) 4 (13.8%) 24 (82.8%) 
Cancer 30 27 24 (88.9%) 5 (18.5%) 25 (92.6%) 
CIN : Cervical lntraepithelial Neoplasia 
t : Score test for trend 
in highly stringent conditions and it is difficult to 
differenciate related viral types (Roman and Fife 
1989). FlSH does not require extraction of DNA 
but it lacks sensitivity. Besides this, FlSH is 
hampered by high background signals (Wagner 
et a / .  1984). The advantage of the in situ 
hybridization technique is the preservation of 
morphology which permits exact location of HPV 
within tissue, but the necessity of biopsy makes 
this method unsuitable for screening purposes. 
The development of polymerase chain reaction 
(PCR) (Saiki et a/. 1985) can be considered as 
one of the major advances in molecular 
virological diagnostics and is known to be more 
sensitive than in situ hybridization or FlSH in the 
detection of HPV DNA. PCR has been used to 
identify as few as 1-2 copies of an HPV genome 
in a sample of only 10 cells and it should allow 
an absolute prevalence of HPV infection to be 
estimated. It also takes less time than FISH. Our 
study was based on direct PCR technique which 
has allowed us to apply this directly on cervical 
scrapes, omitting the laborious DNA purification 
procedure. In agreement with recent available 
data (Van den Brule et a/. 1990; Pasetto et a/. 
1992; Peter et a/. 1989) the prevalence of HPV 
type 16 and 18 increased with the severity of 
pathologic lesion and nearly all cervical cancer 
tissue carries HPV 16 or HPV 18, which 
suggests an important role for these HPV types 
in the development of CIN and cervical cancer. 
But studies performed by different investigators 
show large variations in the prevalence of HPV 
16 and 18 normal cervix and cervical neoplastic 
lesion. The positive rate ranges from 0 % to 80 % 
in normal cervices (Melchers et a/. 1989), and 
from 40% to 100 % in women with cervical 
cancer (Munoz et a/.  1988). While this may 
reflect true geographical prevalence difference, 
it is far more likely that bias is attributed to 
di f ferent definit ions of the normal group,  
contamination during experiment, methodo- 
logical factors in PCR, the HPV subtypes 
inc luded,  and interlaboratory variations. 
Because PCR is a very sensitive method, special 
care must be taken to avoid contamination of 
cl inical  samples dur ing all experimental 
procedures. We used positive and negative 
controls to improve the specificity of the PCR. 
Besides progressive increase in HPV positive 
rate with severity of lesion, HPV 16 is about five 
times more prevalent agent as compared with 
HPV 18 and this is consistent with other report 
(Mark et a/. 1991). 
Even though additional modifications of the 
host cell genes controlling HPV expression are 
required for the development of a malignant 
lesion, HPV infection is suspected as an 
essential etiologic factor. Even though cytologic 
screening is still the most widely used method 
for the early detection of premalignant and 
malignant cervical lesions i t  has some 
limitations, High risk HPV typing in the cervical 
scrapes by direct PCR can be used as a fast 
and sensit ive marker for the presence of 
neoplastic cells and may be able to identify 
women who might carry an increased risk of 
developing cervical cancer. 
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